Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 106

Similar articles for PubMed (Select 23666392)

1.

Advances in antiretroviral therapy.

Arribas JR, Eron J.

Curr Opin HIV AIDS. 2013 Jul;8(4):341-9. doi: 10.1097/COH.0b013e328361fabd. Review.

PMID:
23666392
2.

Combinational therapies for HIV: a focus on EVG/COBI/FTC/TDF.

Schrijvers R, Debyser Z.

Expert Opin Pharmacother. 2012 Sep;13(13):1969-83. doi: 10.1517/14656566.2012.712514. Epub 2012 Jul 31. Review.

PMID:
22849516
3.

Elvitegravir: a once-daily inhibitor of HIV-1 integrase.

Wills T, Vega V.

Expert Opin Investig Drugs. 2012 Mar;21(3):395-401. doi: 10.1517/13543784.2012.658914. Epub 2012 Feb 10. Review.

PMID:
22321026
4.

Drug safety profile of integrase strand transfer inhibitors.

Gutierrez Mdel M, Mateo MG, Vidal F, Domingo P.

Expert Opin Drug Saf. 2014 Apr;13(4):431-45. doi: 10.1517/14740338.2014.897327. Epub 2014 Mar 6. Review.

PMID:
24597519
5.

Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV.

Shah BM, Schafer JJ, Desimone JA Jr.

Pharmacotherapy. 2014 May;34(5):506-20. doi: 10.1002/phar.1386. Epub 2013 Dec 18. Review. Erratum in: Pharmacotherapy. 2014 Jun;34(6):667.

PMID:
24347095
6.

Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single tablet for HIV-1 infection treatment.

Olin JL, Spooner LM, Klibanov OM.

Ann Pharmacother. 2012 Dec;46(12):1671-7. doi: 10.1345/aph.1R468. Epub 2012 Nov 7. Review.

PMID:
23136357
7.

Emerging patterns and implications of HIV-1 integrase inhibitor resistance.

Geretti AM, Armenia D, Ceccherini-Silberstein F.

Curr Opin Infect Dis. 2012 Dec;25(6):677-86. doi: 10.1097/QCO.0b013e32835a1de7. Review.

PMID:
23086187
8.

A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results.

Rockstroh JK, DeJesus E, Henry K, Molina JM, Gathe J, Ramanathan S, Wei X, Plummer A, Abram M, Cheng AK, Fordyce MW, Szwarcberg J; GS-236-0103 Study Team.

J Acquir Immune Defic Syndr. 2013 Apr 15;62(5):483-6. doi: 10.1097/QAI.0b013e318286415c.

PMID:
23337366
9.

Cobicistat-boosted elvitegravir-based fixed-dose combination antiretroviral therapy for HIV infection.

Temesgen Z.

Drugs Today (Barc). 2012 Dec;48(12):765-71. doi: 10.1358/dot.2012.48.12.1895682. Review.

PMID:
23243633
10.

HIV-2 antiviral potency and selection of drug resistance mutations by the integrase strand transfer inhibitor elvitegravir and NRTIs emtricitabine and tenofovir in vitro.

Andreatta K, Miller MD, White KL.

J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):367-74. doi: 10.1097/QAI.0b013e31827b55f1.

PMID:
23187937
11.

An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine.

Rogatto F, Bouee S, Jeanbat V, Piontkowsky D, Aragao F, Bosse M.

J Int AIDS Soc. 2014 Nov 2;17(4 Suppl 3):19779. doi: 10.7448/IAS.17.4.19779. eCollection 2014.

12.

Week 144 resistance analysis of elvitegravir/cobicistat/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive patients.

White KL, Kulkarni R, McColl DJ, Rhee MS, Szwarcberg J, Cheng AK, Miller MD.

Antivir Ther. 2015;20(3):317-27. doi: 10.3851/IMP2885. Epub 2014 Oct 16.

PMID:
25321623
13.

Integrase inhibitors: a novel class of antiretroviral agents.

Schafer JJ, Squires KE.

Ann Pharmacother. 2010 Jan;44(1):145-56. doi: 10.1345/aph.1M309. Epub 2009 Dec 29. Review.

PMID:
20040702
14.

[Integrase inhibitors - new challenges for the treatment of HIV-1 infections].

Stock I.

Med Monatsschr Pharm. 2013 Dec;36(12):448-59; quiz 461-2. Review. German.

PMID:
24450269
15.

Elvitegravir: a once-daily, boosted, HIV-1 integrase inhibitor.

Lampiris HW.

Expert Rev Anti Infect Ther. 2012 Jan;10(1):13-20. doi: 10.1586/eri.11.157. Review.

PMID:
22149610
16.

Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS.

Pandey KK.

HIV AIDS (Auckl). 2014 May 16;6:81-90. doi: 10.2147/HIV.S39178. eCollection 2014. Review.

17.

[Initial antiretroviral therapy in HIV-infected patients].

Cormier H, Hoen B.

Rev Prat. 2014 Oct;64(8):1079-85. French.

PMID:
25510130
18.

Update on raltegravir and the development of new integrase strand transfer inhibitors.

Shamroe CL, Bookstaver PB, Rokas KE, Weissman SB.

South Med J. 2012 Jul;105(7):370-8. doi: 10.1097/SMJ.0b013e318258c847. Review.

PMID:
22766666
19.

Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium.

Nguyen BY, Isaacs RD, Teppler H, Leavitt RY, Sklar P, Iwamoto M, Wenning LA, Miller MD, Chen J, Kemp R, Xu W, Fromtling RA, Vacca JP, Young SD, Rowley M, Lower MW, Gottesdiener KM, Hazuda DJ.

Ann N Y Acad Sci. 2011 Mar;1222:83-9. doi: 10.1111/j.1749-6632.2011.05972.x. Review.

PMID:
21434946
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk